LIQUID BIOPSY SUMMIT

20 - 21 February 2020 | Lisbon, Portugal

BIOTECH PHARMA SUMMIT

On 20 and 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2019 conference.

This year's event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy, molecular pathology and precision medicine experts to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as application of liquid biopsy testing, across biofluids, biomarkers and disease indications, as the needle shifts on the gold standard of personalized healthcare testing.

Latest findings on the clinical applications of CTCs, ctDNA, miRNAs and exosomes in real time monitoring of systemic anticancer therapies will be discussed only at the Liquid Biopsy 2020.

Experts will present and consider process and technology refinements that can enable molecular liquid biopsies to become a fulcrum in the future of precision medicine.

KEY PRACTICAL LEARNING POINTS

- Liquid Biopsy: New Opportunities, Technologies, and Challenges in the Field
- Clinical integration of liquid biopsy
- Circulating Tumor Cells: History and Future Perspectives
- Improving the Quality of Circulating Tumor DNA Measurements
- Circulating Tumor Cells in Monitoring Cancer
- Extracellular vesicles (Evs)
- New Tools for Liquid Biopsies: Microfluidic Platforms for the Isolation of CTCs, cfDNA and Exosomes
- CTC Isolation Platforms and Using CTCs for Monitoring Therapy Responses
- Dissecting Mechanisms of Breast Cancer Metastasis Using Patient-Derived Circulating Tumor Cells
- Liquid Biopsies in Cancer Immunotherapy Clinical Drug Development
- Heterogeneity of Cancer-Derived Extracellular Vesicles
- Liquid Biopsies in Oncology and the Current Regulatory Landscape
- Validating Liquid Biopsies in Cancer
- ctDNA Liquid Biopsy Assay

WHO SHOULD ATTEND

CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists and Medical Doctors of:

- Liquid biopsy
- Clinical Pathology
- Molecular Assay Development
- Medical Laboratory
- Scientific Affairs
- Sales and Marketing
- Quality Management
- Process Development
- Commercial & Outreach, Oncology
- Molecular pathology
- Research Scientist
- Molecular Biology
- Sales & Business Development
- Clinical and Translational Affairs
- Clinical Research
- Companion Diagnostics
- Biomarkers
- Manufacturing
- Scientific Affairs
- Clinical Trial
- Oncology Business Development
- Precision medicine
- Clinical Laboratory
- Immunochemistry
- Cell Culture
- Clinical Genomics

SPEAKERS

DR. FRANÇOISE FARACE

Head of Rare Circulating Cell Translational Platform

at INSERM

FR

DR. ANDERS STÅHLBERG

Associate Professor

at the University of Gothenburg and Sahlgrenska University Hospital in Sweden

SE

PROF. DR. JENS K. HABERMANN

President of ESBB

at Iqvia

DE

PROF. MIKAEL KUBISTA

Chairman of the board and founder

at TATAA Biocenter

SE

DR. LORENA DIÉGUEZ

Group Leader Medical Devices

at INL

PT

DR. ARJAN TIBBE

CEO

at VyCAP

NL

DR. LARA STEVANATO

R&D Manager

at ANGLE plc

UK

DR. CHRISTIAN WERNO

Group Leader, Preclinical Therapy Models

at Fraunhofer-Institut

DE

DR. CARLO BOTTARI

Biomarker Signatures

at NGS- HTG Molecular Diagnostics

UK

DR. RASMUS BRØNDUM

CEO, Founder

at Leymus Genomics

DK

DR. DAGMAR KASPER

Managing Director (EMEA)

at Agena Bioscience

GE

DAVIDE ZOCCO

Chief Technology Officer

at Exosomics

IT

DR. CECILIA SCHOTT

Head Precision Medicine Strategy

at Novartis

US

DR. CLOTILDE COSTA NOGUEIRA

Head of the Liquid Biopsy Line of the Roche

at Chus Joint Unit

ES

DR. DANIEL GRÖLZ

Scientific Associate Director R&D

at QIAGEN

DE

DR. GUOLIANG FU

Founder and CEO

at Genefirst ltd

UK

DR. CATHERINE ALIX-PANABIÈRES

Director of LCCRH

at IURC

FR

SCIENTIFIC AGENDA

Thursday, February 20, 2020 — DAY 1

08:00 Registration and Welcome Coffee

08:50 Opening of the BioTech Pharma Summit

09:00 Liquid Biopsy: Market Trends

*By **Rasmus Brøndum** - CEO, Founder at Leymus Genomics*

- Liquid biopsies 2019
- Requirements for ctDNA analysis - What does extra analytes add to standard ctDNA assays e.g. proteins, RNA
- Market outlook
- Liquid biopsy analyses of human cancer is the future

09:40 Speed Networking

10:20 Morning Coffee & Networking Break

10:50 Clinical Practice is Shaping the Precision Medicine Ecosystem: focus on liquid biopsies

*By **Cecilia Schott** - Head Precision Medicine Strategy, Oncology Business Unit at Novartis*

- New diagnostic platforms are being developed, such as liquid biopsy, to identify the patient most likely to respond to a given treatment
- There is an ever growing need to understand the precision medicine landscape thought the eyes of the practicing clinician
- Geographical differences in the access to various testing modalities and reimbursement must be accounted for in clinical development programs and go-to-market strategies
- An overview of the considerations for the global development and life cycle management of patient diagnostic and monitoring tools

11:30 Precision Medicine Using Liquid Biopsies

*By **Lara Stevanato** - R&D manager at ANGLE plc*

- ParsortixTM system microfluidic technology
- Antigen independent capture of CTCs
- Broad range of downstream analysis (Cytology, immunofluorescence, FISH, and molecular analysis)
- Clinical applications to harvest cancer cells from patient blood and sample to answer (ParsortixTM system plus HyCEAD technology)

12:10 Clinical integration of liquid biopsy

*By **Christian Werno** - Group Leader, Preclinical Therapy Models- Fraunhofer-Institut*

- CTCs are already used to predict disease progression and survival in metastatic patients, however functional analysis of ex vivo expanded CTCs remain challenging. We have generated CTC-derived in vivo and in vitro models from metastatic cancer patients. We have molecularly characterized these models and performed drug screens to improve personalized treatment strategies for metastatic patients in future

12:50 Business Lunch

13:50 Circulating Tumor Cells in Monitoring Cancer

*By **Françoise Farace** - Head of Rare Circulating Cell Translational Platform CNRS UMS3655 at INSERM*

- The identification of predictive biomarkers of sensitivity and resistance to targeted therapies in non-small cell lung cancer, single CTC analyses and CTC-derived xenograft models for a better understanding of the mechanisms of therapeutic resistance and metastatic progression. I think my presentation could fit the session entitled

14:30 Metastasis is responsible for 90% of cancer related deaths

*By **Clotilde Costa Nogueira** - Head of the Liquid Biopsy Line of the Roche at Chus Joint Unit*

- CTCs are responsible for distal metastasis are of great interest for biomarkers discovery to predict and monitor tumor progression and therapy failure. In this study we performed a monitoring of metastatic breast cancer patients before and after treatment througout CTC molecular characterization to identify biomarkers with interest for clinical oncology translation

14:30 Single cell isolation

*By **Arjan Tibbe** - CEO at VyCAP*

- Single cell secretion

15:50 Coffee & Networking Break

16:20 CTC Isolation Platforms and Using

*By **Lorena Diéguez** - Group Leader, Department of Life Sciences, Nano4Health Unit, Medical Devices Research Group, International Iberian Nanotechnology Laboratory*

- CTCs for Monitoring Therapy Responses
- Circulating Tumor Cell isolation and analysis

17:00 Circulating Tumor Cells: Finding Rare Events for a Huge Knowledge of Cancer Dissemination

*By **Catherine Alix** - Panabières is the Director of this unique platform LCCRH- Université de Montpellier, Institut Universitaire de Recherche Clinique (IURC)*

- Technologies for detection of viable Circulating Tumor cells (CTCs)
- Understanding the biology of CTCs
- What about culturing CTCs in vitro to know more about metastasis-competent CTCs ?

17:40 Panel discussion: New Tools for Liquid Biopsies

With speakers of both days

- Advancements in microfluidic technologies
- Microfluidic Platforms for the Isolation of CTCs, cfDNA and Exosomes
- Progress in Circulating Tumor Cell Research Using Microfluidic Devices on clinical research parameters, such as survival statistics

18:00 Chairman's Closing Remarks

19:00 Gala Dinner

Friday, February 21, 2020 DAY 2

08:00 Registration & Coffee

08:30 Opening Address from the Chairperson

08:40 Circulating tumor DNA- preanalytical considerations, international specimen improvement requirements, standards, legislation, technologies

*By **Daniel Grölz** - Scientific Associate Director R&D, Sample Technologies Department at QIAGEN*

- Need of specimen quality improvement to reduce diagnostic errors
- Pre-analytical factors that influence the outcome of ccfDNA analysis
- International initiatives and requirements to standardize pre-analytical workflows
- Liquid biopsy preservation and workflow solutions

09:20 Technical and biological challenges when analyzing cell-free tumor DNA

*By **Anders Ståhlberg** - Associate Professor at the University of Gothenburg and Sahlgrenska University Hospital in Sweden*

- Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA
- We have developed SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input. Here, we will present recent updates
- Here, we discuss important considerations for ctDNA analysis in plasma, including all experimental steps from sampling to data interpretation. Furthermore, the use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine
- We will show data from various ongoing studies, related to both clinical and basic research questions

10:00 Liquid Biopsies in Cancer Immunotherapy Clinical Drug Development

*By **TBA***

- Robustness, reproducibility and consistency across laboratories
- The expected standards for analytical validation of a liquid biopsy assay
- ctDNA and CTC strengths and weaknesses

10:40 Morning Coffee and Networking Break

11:10 Extracellular vesicles (EVs)

*By **Davide Zocco** - Chief Technology Officer- Exosomics*

- The performance of common exosome isolation methods
- The integration of microfluidics and various sensing components or sensors
- Microfluidic isolation of Evs
- On-chip detection and analysis of Evs

11:50 Two-Tailed PCR for Precision Diagnostic

*By **Mikael Kubista** - Chairman of the board and founder at TATAA Biocenter*

- Two-Tailed PCR
- Ultra-sensitive microRNA profiling
- Ultra-specific rare mutation analysis
- Quality assessment of liquid biopsy testing

12:30 Quantitative miRNA Profiling

*By **Carlo Bottari** - Biomarker Signatures, Molecular Diagnostics, CDx, Precision Medicine, Early Cancer Detection, Molecular Profiling, NGS at HTG Molecular Diagnostics*

- Methods and Challenges

13:10 Business Lunch

14:10 Applications of CTCs and ctDNA as a Non-Invasive Tumor Tracker

*By **Dagmar Kasper** - Managing Director (EMEA) at Agena Bioscience*

14:50 Targeting tumor heterogeneity and applying liquid biopsies

*By **Jens K Habermann** - President of ESBB at Iqvia*

15:30 Coffee & Networking Break

16:00 Novel Technologies

*By **Guoliang Fu** - Founder and CEO- genefirst ltd*

- MMD-PCR (Multiplex Mutation Detection PCR)

17:40 Panel discussion: Conclusions and future directions

With speakers of both days

- Relevancy to utilize CTCs and ctDNA during systemic therapy rather than as early diagnosis markers
- Tests for mutations in genes encoding therapeutic targets
- A paradigm shift in liquid biopsy research with EVs or ctDNA being preferred markers over CTC
- Technical challenges involved in removing Evs

17:00 Chairman's Closing Remarks & End of Summit

BIOGRAPHIES

CHRISTIAN WERNO, DE
Group Leader, Preclinical Therapy Models at Fraunhofer-Institut

Dr. rer. med. Christian Werno is research group leader “Preclinical Therapy Models”, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Division of Personalized Tumor Therapy. He got his PhD at Goethe University Frankfurt am Main, then being a postdoctoral fellow at Fraunhofer ITEM Regensburg Division of Personalized Tumor Therapy.

FRANÇOISE FARACE, FR
Head of Rare Circulating Cell Translational Platform at INSERM

Françoise Farace is currently in charge of the Translational Laboratory of Rare Circulating Cells at CNRS UMS3655 - INSERM US23 AMMICA, and of the Circulating Tumor Cells team at INSERM U981, Gustave Roussy. For the past fourteen years, FF focused her research on rare circulating cells such as circulating endothelial cells and circulating tumor cells with the goal of identifying both sensitivity and resistance biomarkers of anticancer therapies.

ANDERS STÅHLBERG, SE
Associate Professor at the University of Gothenburg and Sahlgrenska University Hospital in Sweden

Anders Ståhlberg is working as principal investigator at the Sahlgrenska Cancer Center, University of Gothenburg and Sahlgrenska University Hospital in Sweden. Anders primary research interest is to understand molecular mechanisms in tumor initiation and tumor development, focusing on breast cancer and sarcomas. He has developed several strategies for DNA and RNA, especially at the single-cell and single-molecule level.

JENS K. HABERMANN, DE
President of ESBB at Iqvia

Professor Jens K. Habermann, m.d., Ph.D., is director of ICB-L (Interdisciplinary Center for Biobanking-Lübeck) and scientific director of UCCL (University Cancer Center Lübeck) at the University of Lübeck and University Clinic Schleswig-Holstein. As specialist in human genetics, he combines clinical routine, biobanking, and cancer research to optimize individualized medicine by targeting tumor heterogeneity and applying liquid biopsies.

MIKAEL KUBISTA, SE
Chairman of the board and founder at TATAA Biocenter

In 1996 Kubista invented the light-up probes, which led to the foundation of LightUp Technologies AB as Europe´s first company focusing on qPCR based diagnostics. He co-founded MultiD Analyses AB, which develops the market leading software GenEx for molecular analysis, and in 2001 Kubista set up TATAA Biocenter as the first laboratory in Europe to obtain flexible ISO 17025 accreditation.

ARJAN TIBBE , NL
CEO at VyCAP

After completing his PhD in 2001, Arjan established and managed Im-municon Europe, Enschede, the Netherlands, a subsidiary of Immunicon Corporation, USA. Immunicon developed the FDA cleared CellSearch system for monitoring metastatic cancer by measuring the number of CTC. Immunicon was ac-quired by Veridex, a Jonhson & Johnson company, in 2008 where he held the same position within the Enschede facility.

CARLO BOTTARI, UK
Biomarker Signatures at NGS- HTG Molecular Diagnostics

Having gained a BSc in biochemistry, over the past 18 years, Carlo has been working in sales and marketing in the scientific technology industry. In his role at HTG he is focused on Molecular Profiling, Biomarker Signature Development and Molecular Diagnostic Applications, including development of applications in Liquid Biopsy, Early Disease Detection, Companion Diagnostics and Precision Medicine.

LARA STEVANATO , UK
R&D Manager at ANGLE plc

Lara Stevanto possesses a PhD in Biotechnology. She joined ANGLE PLC in 2016 as R&D project manager for the analytical evaluation of ParsortixTM system as part of the FDA application. As part of Cancer-ID, she led the protocol development for the CTC isolation and enumeration technology comparison (CANCER-ID Ring Trial). Prior to joining ANGLE, Lara served as Head of Molecular Biology at ReNeuron, specializing in the development of stem cell-based clinical products.

CATHERINE ALIX-PANABIÈRES , FR
Director of LCCRH at IURC

During this last decade, Dr Alix-Panabières has focused on optimizing new techniques of enrichment, detection and characterization of viable circulating tumor cells (CTCs) in patients with solid tumors. She is the expert for the EPISPOT technology that is used to detect viable CTCs in patients with breast, prostate, colon, head & neck cancer and melanoma. This technology has been recently improved to detect functional CTCs at the single cell level (EPIDROP).

RASMUS BRØNDUM, DK
CEO, Founder at Leymus Genomics

Rasmus Brøndum, Molecular Biologist by training has worked for the leading companies in the genomic industry includ-ing companies such as Thermo Fisher Scientific, Illumina and Roche. At Roche as a director in Molecular Diagnostics he was part of a regional team launching worlds first liquid biopsy (Cobas™ EGFR mutation test). In 2016 he founded his own company Leymus Genomics which provides products for long read sequencing on Illumina sequencers and also big data on site storage for mainly clinical and national genome projects.

CLOTILDE COSTA NOGUEIRA, ES
Head of the Liquid Biopsy Line of the Roche at Chus Joint Unit

Clotilde is a Biologist. In 2011 I developed my phD in Molecular Oncology at CIEMAT (Madrid) focused on the study of cell cycle genes in squamous cell carcinomas. In 2013 she moved to Santiago de Compostela to the Translational Medical Oncology Group to work in the study of metastasis through Liquid Biopsy. Since 2015 she is the leader of the Liq-uid Biopsy Line at the Joint Unit Roche-Chus, University Clinical Hospital of Santiago, focused on the understanding of the biology of Circulating Tumor Cells of metastatic Breast and Prostate patients.

DAVIDE ZOCCO, IT
Chief Technology Officer at Exosomics

Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&D pipeline the develop-ment of molecular assays for detection of EV shuttled mutations. In 2015 he took on the role of the Head of Molecular Diagnostics. Today he is responsible for development of EV-DNA and EV-RNA targeted solutions and for management of clinical testing of assay prototypes. Davide actively participates in scouting for new technologies, as well as internal IP strategy and pre-market launch of RUO and diagnostic kits.

LORENA DIÉGUEZ, PT
Group Leader Medical Devices at INL

Lorena Diéguez joined INL in 2014 as Staff Researcher and is, since May 2018, the leader of the Medical Devices research group. Her research is focused in the development of biomicrofluidic devices mainly devoted to Translational Medical Research in close collaboration with Hospitals. Her work is devoted to the development of integrated biosensing systems and nanobioengineered diagnostics microsystems for the isolation and characterization of Tumor Cells from body fluids of cancer patients, as well as the development of microfluidic organ-on-a-chip 3D models.

DANIEL GRÖLZ, DE
Scientific Associate Director R&D at QIAGEN

Dr. Grölz is the R&D project manager who led an international team within PreAnalytiX GmbH to develop the PAXgene Tissue and the PAXgene Blood ccfDNA Systems. He was the leader for the evaluation of the PAXgene Tissue System within the European collaborative grant project, SPIDIA, and manages work packages in two other grant projects to evaluate the PAXgene Tissue and PAXgene Blood ccfDNA Systems for use in routine pathology workflows. He is the main inventor of the PAXgene Tissue System and inventor/co-inventor of the PAXgene Blood ccfDNA stabilization chemistry.

CECILIA SCHOTT, US
Head Precision Medicine Strategy at Novartis

Cecilia is Head Precision Medicine Strategy Oncology Business Unit at Novartis. Prior to her current role Cecilia held positions VP, Precision Medicine for AstraZeneca Global Product & Portfolio Strategy, Global Marketing and US Medical Affairs. Cecilia background includes roles in the biotech and device industries. Before joining AstraZeneca she was part of Biogena Drug Safety and Medical Information function, and at Boston Scientific she was responsible for establishing the drug eluting stent franchise Medical Publications and Medical Information groups as part of Medical Affairs.





REGISTRATION

PACKAGE NAME

Title:		Title:	
Name:		Name:	
Position:		Position:	
E-mail:		E-mail:	

Company:			
Address:		Postcode:	
City:		Phone	
VAT No:		Gala Dinner	Yes ☐ No ☐
Signature:		Date	dd - mm - yyyy

This booking is invalid without signature

Diogo Lino Ribeiro
Project Director, Europe | Porto Office
EM: diogo.ribeiro@epmgroup.org
PH: +351 915 239 640

**Please send the signed form to this contact.*

ACADEMIC/ MED./ NPO PACKAGE
Individual or Group Registration

2 days Summit	✓
Full-Access to All Sessions	✓
Coffee Breaks/Lunches	✓
Gala Dinner (Extra 50€)	×
Unique 1-on-1 meetings	×
Airport Pick-Up/Drop-Off	×
Accommodation at the Hotel Venue	×

BOOK NOW

INDUSTRY BASIC PACKAGE
Individual Registration

2 days Summit	✓
Full-Access to All Sessions	✓
Coffee Breaks/Lunches	✓
Gala Dinner	✓
Unique 1-on-1 meetings	✓
Airport Pick-Up/Drop-Off	×
Accommodation at the Hotel Venue	×

BOOK NOW

INDUSTRY PREMIUM PACKAGE
Individual Registration

2 days Summit	✓
Full-Access to All Sessions	✓
Coffee Breaks/Lunches	✓
Gala Dinner	✓
Unique 1-on-1 meetings	✓
Airport Pick-Up/Drop-Off	✓
Accommodation at the Hotel Venue	✓

BOOK NOW

	Super Early Bird Until Nov 15	*Early Bird* Until Dec 13	*Discounted Ticket* Until Jan 31	*Normal Ticket* After Jan 31
Academic/ Med./ NPO Package	500€	600€	650€	850€
Industry Package	1,495€	1,695€	1,795€	1,995€
Premium Package	2,800€	3,000€	3,250€	3,550€

The **Liquid Biopsy Summit is an exclusive limited seat event. Early bird tickets are non-refundable and subject to availability*

Team Discounts	Until Nov 15	Until Dec 13	Until Jan 31	After Jan 31
2 Delegates	10%	5%	-	-
3 Delegates	15%	10%	5%	-
4+ Delegates	20%	15%	10%	5%

All Prices displayed include VAT @ The VAT amount will be displayed after the payment process and shown on your invoice.

SPONSORSHIP PACKAGES

GOLD SPONSORSHIP
(VAT INC.) **15,995€**

- Opportunity to give a speech at the beginning of the conference [up to 40min]
- 8m2 exhibition space with LCD Monitor for Video Presentations
- FULL page Ad in conference program
- Company Banner displayed at all the Sessions including Gala Dinner
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- **Up to 5 delegates FREE-Admission** (25% discount for extra ticket)
- VIP Airport Pick-up Service
- **2 nights** accommodation for **5** delegates registered

SILVER SPONSORSHIP
(VAT INC.) **12,995€**

- Speaking slot [up to 40min]
- 6m2 exhibition space with LCD Monitor for Video Presentations
- ½ page Ad in conference program
- Company Banner displayed at the reception desk & Coffee breaks
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- **Up to 4 delegates FREE-Admission** (25% discount for extra ticket)
- VIP Airport Pick-up Service
- **2 nights** accommodation for **4** delegates registered

BRONZE SPONSORSHIP
(VAT INC.) **8,995€**

- Speaking slot [up to 40min]
- 6m2 exhibition space
- ¼ page Ad in conference program
- Company Banner displayed at the reception desk
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- **Up to 3 delegates FREE-Admission** (25% discount for extra ticket)
- VIP Airport Pick-up Service
- **2 nights** accommodation for **3** delegates registered

SPEAKER SPONSORSHIP
(VAT INC.) **5,995€**

- Speaking slot [up to 40min]
- 3m2 exhibition space
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- **Up to 2 delegates FREE-Admission** (25% discount for extra ticket)

KEYNOTE SPEECH PACKAGE
(VAT INC.) **3,550€**

- Speaking slot [up to 40min]
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- **Up to 1 delegates FREE-Admission** (25% discount for extra ticket)

EXHIBITION PACKAGE
(VAT INC.) **3,550€**

- 3m2 exhibition space
- Logo on the conference website and main stage
- Flyer/promo gifts into congress bags
- Branding at post-event communication activities
- Access to all Sessions
- Business Lunches & Gala Dinner
- Exclusive One-on-One Meetings
- **Up to 1 delegates FREE-Admission** (25% discount for extra ticket)

Click bellow to register as a sponsor

ONLINE REGISTRATION

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.

Confirmation
We will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.

Cancellations
Cancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

Force Majeure
While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made.

Copyright

biotechpharmasummit.com